Study: Better Use of 340B Can Help Shrink Urban “Pharmacy Deserts”

A new study in Health Affairs says there is a role for the 340B program for eliminating “pharmacy deserts” in Black and Hispanic/Latino urban neighborhoods. | Shutterstock

Policymakers should make better use of the 340B program to help eliminate “pharmacy deserts” in Black and Hispanic/Latino urban neighborhoods, new research published in Health Affairs recommends.

The study was conducted by researchers at four universities and supported by the

Read More »

Expect to Hear a Lot About Drug Pricing During Next Week’s House Hearing With Becerra

House E&C Chair Frank Pallone (D-N.J.), speaking remotely from his home, said during a hearing this week that he looks forward to enacting the House Democrats' drug pricing legislation, H.R. 3, this year.

A powerful U.S. House health subcommittee has invited U.S. health secretary Xavier Becerra to brief it next week about his department’s discretionary budget request for the coming fiscal year, and to discuss how they might collaborate on lowering drug prices

Read More »

State Attorney General Is Investigating Lilly and AstraZeneca’s 340B Pricing

Eli Lilly and AstraZeneca are the latest drug makers to disclose that they have been subpoenaed by Vermont's top law enforcement official for documents and information about their participation in 340B. | Shutterstock

Eli Lilly and AstraZeneca are the latest drug makers to disclose they have received a subpoena from the Vermont attorney general’s office related to their denials of 340B ceiling prices on drugs shipped to contract pharmacies.

Lilly and

Read More »

Hospital Groups Want FDA to Curtail Specialty Drug White Bagging

Hospital groups are growing more concerned about white bagging—the payer practice of requiring them to obtain specialty drugs, often for cancer treatment, from the payer's chosen specialty pharmacies. | Shutterstock

The American Hospital Association (AHA) and ASHP (the American Society of Health-System Pharmacists) want the U.S. Food and Drug Administration (FDA) to “take appropriate action” against white bagging—the health care payer requirement that hospitals obtain specialty drugs for insured patients

Read More »

Arkansas Passes First-of-its-Kind Bill to Counter Pharma’s 340B Contract Pharmacy Moves

Arkansas state lawmakers this week passed what is thought to be the first bill in the nation to address drug manufacturers' denials of 340B pricing on drugs dispensed by contract pharmacies. | Jim Bowen/Flickr

The Arkansas legislature on Tuesday passed what is believed to be the first bill nationally to address pharmaceutical manufacturer denials of 340B pricing on drugs when they are dispensed by contract pharmacies.

The state Senate passed the bipartisan bill,

Read More »

Vermont AG Issues Subpoena to Novartis for 340B Documents and Information

Novartis is the second known drug manufacturer subpoenaed by the Vermont attorney general over manufacturer denials of or restrictions on 340B pricing for drugs shipped to contract pharmacies.

Vermont’s top law enforcement official has asked a second drug manufacturer—Novartis—for documents and information concerning the company’s participation in the 340B program in the state.

Tuesday in its interim financial report for the first quarter of 2021, the Swiss

Read More »

Biden Wants to Let Medicare Negotiate Drug Prices, but Not Via His American Families Plan

President Biden applauds Vice President Kamala Harris and House Speaker Nancy Pelosi prior to his speech before a joint session of Congress last night. The event marked the first time in history that two women were seated in the two positions of authority and honor directly behind the president during such a speech. | @POTUS Twitter

President Biden has left out of his American Families human-capital investment plan drug pricing reforms that Democratic leaders in Congress have pressed him hard to add. House Speaker Nancy Pelosi (D-Calif.), House Energy and Commerce (E&C) Chair Frank Pallone (D-N.J.),

Read More »

Hospitals Could Get Another Shot to Intervene in AstraZeneca’s 340B Lawsuit

A federal judge in Delaware yesterday left the door open to letting hospital groups participate as third parties in a drugmaker’s lawsuit challenging the federal government’s 340B program contract pharmacy enforcement mechanisms. | Shutterstock

A federal judge in Delaware yesterday declined to add hospital groups as third parties to a drugmaker’s lawsuit challenging the federal government’s 340B program contract pharmacy enforcement mechanisms. But he left the door open to letting the groups participate as

Read More »

Nonprofit Generic Drugmaker Civica Is Providing Refunds for 340B Overcharges

Nonprofit generic drug manufacturer Civica said it has updated its 340B pricing as it obtains baseline average manufacturer price (AMP) data from generic drug manufacturers that make the same products. | Marco Verch https://www.flickr.com/photos/30478819@N08/

Civica, the nonprofit generic drug manufacturer that health systems created in response to drug shortages, owes 340B covered entities refunds for overcharges on 13 NDCs from April 13, 2020 through Feb. 23, 2021.

Civica posted a public notice this

Read More »

Will Biden’s American Families Plan Include an Rx Drug Pricing Measure?

There is a rift between President Biden and House Democrats over whether to include provisions to lower drug prices in his American Families plan, or deal with drug pricing later in another bill. | Official White House Photo by Adam Schultz

President Biden might exclude legislation to reduce what consumers and the federal government pay for prescription drugs from his American Families human and capital investment initiative, news organizations report this morning. Biden is scheduled to describe his infrastructure investment plan

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live